Friday brought a little of everything: a cost-cutting headline here, a canceled party there, and a stubborn worry humming in the background. Nobody quite panicked, though plenty of traders eyed the exits and wondered what the central bank might do next. 

Read on to find out who flinched first and why a few household names had such a rough day.

One analyst believes Elon Musk is preparing to launch the biggest project of his career — and says the key date is December 8.

Why December 8

He claims the clues are already buried in government filings, along with one investment move he believes is worth considering before December 9.

See the filings

His full case is laid out in a free masterclass.

See What Elon Filed Before December 8

American Express joined the week’s layoff parade, cutting about 5% of its workforce, roughly 3,500 jobs, and its stock slid, dragging the Dow lower. In chips, SK Hynix yanked the planned U.S. IPO of its memory business, a sign the AI party is getting pickier about the guest list. 

Bonds from Oracle, SpaceX and Meta kept demanding fatter premiums, while Treasury yields hovered around 5% and the Fed is expected to hold rates Wednesday and resume hiking in December.

Brent crude climbed above $116, its highest since April, as the U.S. sent more forces to the Middle East and Iran issued fresh threats. Moderna executives sold over $30 million of stock under pre-set plans before detailed vaccine results trimmed the gains.

Meta delayed new commercial and advertising terms until November 20 after publishers raised concerns about how their content could be used for AI, giving the company more time to explain the changes before they take effect.

RingCentral raised its annual revenue outlook after quarterly sales reached $676 million, with AI-powered business communications supporting its expansion as the company develops automated receptionists and tools that analyze customer conversations.

JPMorgan received preliminary approval to establish a merchant bank in Nigeria, advancing its expansion into wholesale banking and capital markets, although final licensing and operational approvals remain outstanding.

Wells Fargo has objected to tokenizing its shares on the proposed OKXICE trading platform, joining other companies declining to participate in blockchain-based stock trading.

SLB’s data-center business grew 76% from a year earlier, with revenue also increasing 23% from the previous quarter, strengthening an emerging business beyond its established oilfield equipment and services operations.

Comfort Systems USA reported a $17.81 billion backlog as quarterly revenue reached $3.77 billion, with mechanical and electrical construction demand supporting substantial growth across the contractor’s commercial, industrial, and institutional operations.

Only a tiny percentage of stocks meet the criteria for this report.

Analysts have released a new edition highlighting seven names selected using multiple indicators.

Recent picks have delivered notable short-term gains, though results can vary.

The latest report is now available for a limited time.

Download the free report today.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.

*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Tesla’s better-than-expected automotive profit margin benefited from a one-time tariff refund, according to Barron’s analysis of its quarterly results, making the reported improvement a less reliable measure of recurring manufacturing profitability.

Lyft’s Freenow and Baidu demonstrated their RT6 robotaxi in London, outlining plans for fully driverless commercial service in 2027, following tests with safety drivers that began during the summer.

Lycia Therapeutics began Nasdaq trading after raising approximately $318 million in its IPO, with shares priced at the top of its proposed range as the company develops treatments for autoimmune and inflammatory diseases.

Gilead agreed to acquire PepStar Therapeutics’ oral inflammation drug program for $1.275 billion upfront, adding an experimental bowel-disease treatment that could be developed independently or combined with other medicines in its pipeline.

Robert Half [RHI] $45.87 (+21.74%)

Robert Half finally gave staffing watchers something to smile about. Third quarter talent solutions revenue grew on an adjusted basis for the first time since 2022, and earnings climbed to 49 cents a share from 43 cents.

The CEO says hiring is gradually improving. After a long stretch of holding its breath, investors exhaled and bought.

BUUU Group [BUUU] $53.90 (+18.34%)

BUUU Group, a Hong Kong event services company, is getting its share price a makeover.

A 10-for-1 forward split takes effect October 27, and traders piled in ahead of it, which is how split season usually goes. A split changes the price tag, not the business, but never underestimate how much people love a smaller number.

YD Bio [YDES] $4.95 (+15.86%)

YD Bio bounced back from a rough ride. Shares had dropped sharply the day before, so this looks like bargain hunters wading back in.

The biotech has also been busy, partnering with EG BioMed and JoiiUp on an AI-driven cancer risk assessment for corporate wellness programs. Not a clinical breakthrough, but apparently enough to lure buyers back.

LKQ Corporation [LKQ] $17.42 (-22.47%)

LKQ had a pileup of a day. Preliminary third-quarter results disappointed, mostly because of Europe; the full-year outlook was withdrawn, and CEO Justin Jude is out, with a successor starting December 15.

A $111 million impairment charge and consultants reviewing European operations did not calm nerves. The board admitted performance fell well short of its expectations.

Regencell Bioscience [RGC] $7.67 (-21.81%)

Regencell is the stock that never sits still. The Hong Kong developer of traditional Chinese medicine formulas for ADHD and autism, with no product revenue yet, jumped about 17% last Thursday, then handed some back.

Friday’s drop looks like the hangover from a wild week. Its annual loss widened to $11.7 million, so the thrill ride has a price tag.

Corcept Therapeutics [CORT] $85.86 (-20.13%)

Corcept got elbowed by a rival. Genmab reported positive Phase 3 results for its ovarian cancer drug in platinum-resistant patients, the same group Corcept’s newly approved Lifyorli targets.

Suddenly the competition looks real, and Genmab shares rallied while Corcept sank, and an analyst downgrade last month did not help. Investors prefer an empty field, and the field just got crowded.

Whitney Tilson shocked the nation on 60 Minutes when he accused a major company of poisoning its customers.

The investigation won an Emmy and the stock fell nearly 80%. (He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers).

Now, he's releasing his next big story. He says the day after our upcoming midterm elections, America will enter a period of economic change unlike anything we've seen in decades.

And most investors are unprepared for what's coming. For the full presentation, go here.

*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.